Vifor Pharma

Robust finish to FY18; mid-term financial targets within reach

15/03/19 -"Vifor reported strong FY18 results with revenue as well profits exceeding the already raised targets – driven by Ferinject, Veltassa and VFMCRP. The positive growth momentum is likely to continue in ..."

Published on
You may also be interested by these reports :
Despite our lower EPS19, the target price moves slightly up driven by the higher earnings from 2020 onwards, and the higher DCF and SOTP valuations.

The high uncertainty of the final decisions on the lawsuits triggers the change of our Add to Reduce due to the vague payments. The lower valuation ...

We have clearly reduced the amount of the expected impairments for the coming years, especially in 2019, as management missed the chance to tidy up ...

The last one year has been a roller-coaster ride for the pure-play biotech, Genmab (Add, Denmark). While an R&D setback (two studies discontinued) in ...


Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis


AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO